PureCycle Technologies, Inc. (PCT) - 10-Q Summary for Period Ended June 30, 2026
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for PureCycle Technologies, Inc., a Florida-based corporation commercializing patented dissolution recycling technology to produce PureFive® resin from polypropylene waste. The report covers the quarterly period ended June 30, 2026, and the six-month period ended on the same date. The company operates a single commercial-scale facility in Ironton, Ohio, and is in the development phase for facilities in Thailand, Belgium, and Augusta, Georgia.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Revenues | $4.5 million | $8.6 million |
| Net Loss | $(142.2) million | $(175.7) million |
| Operating Loss | $(41.3) million | $(83.1) million |
| Loss Per Share (Basic & Diluted) | $(0.80) | $(1.02) |
| Cash and Cash Equivalents | $165.2 million (as of June 30, 2026) | N/A |
| Total Debt (Long-term + Current) | $359.5 million (Long-term Debt) | N/A |
| Related Party Bonds Payable | $110.7 million (Gross) | N/A |
| Net Cash Used in Operating Activities | N/A | $(92.7) million |
Note: The company reported a significant "Loss on extinguishment of debt" of $34.5 million in the second quarter due to the repurchase of Green Convertible Notes.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 173% year-over-year for the quarter ($4.5M vs. $1.7M) and 167% for the six-month period ($8.6M vs. $3.2M), driven by increased production volumes (4.5M lbs in Q2 2026 vs. 3.4M lbs in Q2 2025) and customer application trials.
- Debt Restructuring: In June 2026, the company issued $287.5 million in 4.75% Convertible Senior Notes due 2032. Concurrently, it repurchased $216.0 million of its Green Convertible Notes, resulting in a $34.5 million loss on extinguishment of debt.
- Equity Issuance: The company completed a Common Stock Offering in June 2026, issuing approximately 19.9 million shares at $8.21 per share, generating gross proceeds of $163.0 million.
- Legal Settlement: The company settled the Denham-Blythe arbitration matter in April 2026, paying $20.3 million. This resolved a significant contingency that had impacted legal costs in the prior year.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses decreased by $6.2 million in the quarter compared to the prior year, primarily due to lower equity-based compensation and reduced legal costs associated with the resolved arbitration.
Guidance, Outlook, and Risks
Outlook and Capital Resources: Management states that current financial projections support the ability to meet obligations for at least the next 12 months. The company holds approximately $236.9 million in cash, restricted cash, and marketable securities as of June 30, 2026, plus an undrawn $200.0 million revolving credit facility with Sylebra.
Strategic Developments:
- Thailand Facility: Admitted to the Thailand FastPass Investment Acceleration Program; expected operational in 2028.
- Belgium Facility: Signed a €40 million grant agreement with the European Climate, Infrastructure and Environment Executive Agency (CINEA); expected operational in 2029.
- Augusta Facility: Design in process for a 300 million lb/year facility; mechanical completion expected by 2030.
Risks and Contingencies:
- Profitability: The company is an early commercial-stage entity with no history of profitability and expects to continue incurring losses.
- Regulatory Approval: Continued reliance on FDA Letters of No Objection (LNOs) for food-grade applications and pending European regulatory approvals.
- Operational Execution: Risks related to scaling the Ironton Facility to full capacity and achieving consistent quality parameters (specifically odor and color).
- Warrant Liability: Significant volatility in the fair value of liability-classified warrants impacted net loss, with a $52.5 million increase in fair value recorded in Q2 2026.
Investor Verification Checklist
- Debt Covenants: Verify compliance with covenants under the new Convertible Senior Notes and the Sylebra Revolving Credit Facility, particularly given the high leverage and ongoing construction costs.
- Production Metrics: Confirm the ramp-up of the Ironton Facility to nameplate capacity and the consistency of PureFive® resin quality (specifically odor specifications) to secure long-term offtake agreements.
- Regulatory Status: Monitor the status of FDA LNOs for new feedstock types and the progress of European regulatory authorizations for the Belgium facility.
- Capital Expenditures: Track the burn rate against the $236.9 million liquidity position to ensure sufficiency for the construction of the Thailand, Belgium, and Augusta facilities.
- Warrant Valuation: Assess the impact of stock price volatility on the recurring fair value adjustments of the Series A, B, and C warrants, which significantly distort net income/loss.